Baird raised the firm’s price target on Castle Biosciences to $34 from $33 and keeps an Outperform rating on the shares. The firm said they reported 1Q revenue ahead of expectations, though DecisionDx-Melanoma and DecisionDx-SCC volumes came in below the Baird model, with the company citing typical seasonality and national sales meeting timing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences Unveils Informative Management Presentation Slides
- Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverage
- Castle Biosciences Secures Loan and Reshuffles Board
- Castle Biosciences management to meet virtually with Stephens
- Castle’s DecisionDx-SCC study shows predictive accurracy with patients